Zenas reports strong phase 3 results for obexelimab in IgG4-related disease

5th January 2026 Uncategorised 0

Company prepares regulatory filings after treatment shows significant reduction in disease flare risk

More: Zenas reports strong phase 3 results for obexelimab in IgG4-related disease
Source: News